Associate Professor, Internal Medicine, Mayo Medical School
Hematology
Dr. John A. Lust, MD
|
|
Give Review
John A. Lust, MD works in the field of Hematology. He graduated from Boston University School of Medicine. Boston University School of Medicine is ranked 30 in research and 52 in primary care medicine John Lust is also published. He has 76 publications published. The lastest publication: "Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma.' John Lust accepts Medicare payments and is registered with Medicare.gov.
Publications
- Outcomes of primary refractory multiple Myeloma and the impact of novel therapies.
- Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple Myeloma.
- Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis.
- Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias.
- Trends in survival of patients with primary plasma cell Leukemia: a population based analysis.
- High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis.
- Long-term Disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy.
- Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant.
- Continued improvement in survival in multiple Myeloma: changes in early mortality and outcomes in older patients.
- Smoldering multiple Myeloma requiring treatment: time for a new definition?
- A detailed evaluation of the current Renal response criteria in AL amyloidosis: is it time for a revision?
- Outcomes of patients with POEMS Syndrome treated initially with radiation.
- Localized Tongue Amyloidosis: A Single Institutional Case Series.
- Management of newly diagnosed symptomatic multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
- Impact of Primary Molecular Cytogenetic Abnormalities and Risk of Progression in Smoldering Multiple Myeloma.
- Systemic amyloidosis associated with chronic lymphocytic Leukemia/small lymphocytic lymphoma.
- A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple Myeloma.
- Trends and outcomes of modern staging of solitary plasmacytoma of bone.
- Trisomies in multiple Myeloma: impact on survival in patients with high-risk cytogenetics.
- Immunoglobulin D amyloidosis: a distinct entity.
- The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS Syndrome.
- Reduction in plasma cell proliferation following initial therapy in newly diagnosed multiple Myeloma measures treatment response and predicts improved survival.
- Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory Disease.
- Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple Myeloma: Results from a phase 2 trial.
- Recent improvements in survival in primary Systemic amyloidosis and the importance of an early mortality risk score.
- Specificity of serum and urine protein electrophoresis for the diagnosis of monoclonal gammopathies.
- Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with Immune mo...
- Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) Myeloma.
- Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed Myeloma.
- Diagnosis and management of Waldenström Macroglobulinemia: Mayo stratification of Macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
- Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple Myeloma: a comparative analysis of 411 patients.
- Management of newly diagnosed symptomatic multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.
- Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple Myeloma.
- Screening panels for detection of monoclonal gammopathies.
- Impact of risk stratification on outcome among patients with multiple Myeloma receiving initial therapy with lenalidomide and dexamethasone.
- Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.
- Induction of a Chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the...
- Short communication: Absence of evidence of HTLV-3 and HTLV-4 in patients with large granular lymphocyte (LGL) Leukemia.
- A novel report of cig-FISH and cytogenetics in POEMS Syndrome.
- Improved survival in multiple Myeloma and the impact of novel therapies.
- Intracardiac Thrombosis and embolism in patients with cardiac amyloidosis.
- Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed Myeloma.
- Intestinal lymphangiectasia with protein-losing enteropathy in Waldenstrom Macroglobulinemia.
- Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus Statement.
- The activity of lenalidomide with or without dexamethasone in patients with primary Systemic amyloidosis.
- Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays.
- Mayo clinic consensus Statement for the use of bisphosphonates in multiple myeloma.
- Clinical implication of centrosome amplification in plasma cell neoplasm.
- Natural history of thromboembolism in AL amyloidosis.
- Identification of two groups of smoldering multiple Myeloma patients who are either high or low producers of interleukin-1.
- Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed Myeloma.
- Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple Myeloma.
- Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance.
- Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.
- Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary Systemic amyloidosis undergoing peripheral bl...
- Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging System for primary Systemic amyloidosis.
- Clinical course of patients with relapsed multiple Myeloma.
- Superior survival in primary Systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.
- Flow cytometric assessment of TCR-Vbeta expression in the evaluation of peripheral blood involvement by T-cell lymphoproliferative Disorders: a comparison with convent...
- Poor tolerance to high doses of thalidomide in patients with primary Systemic amyloidosis.
- Expression of CD52 on plasma cells in plasma cell proliferative Disorders.
- Aplastic anemia and pure red cell aplasia associated with large granular lymphocyte Leukemia.
- POEMS Syndrome: definitions and long-term outcome.
- Oncolytic measles viruses displaying a single-chain antibody against CD38, a Myeloma cell marker.
- Prognostic value of angiogenesis in solitary bone plasmacytoma.
- Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary Systemic amyloidosis.
- Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple Myeloma.
- Review of 1027 patients with newly diagnosed multiple Myeloma.
- Primary follicular mucinosis: long-term follow-up of patients younger than 40 years with and without clonal T-cell receptor gene rearrangement.
- Combination therapy with thalidomide plus dexamethasone for newly diagnosed Myeloma.
- Genomic abnormalities in monoclonal gammopathy of undetermined significance.
- Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple Myeloma, and primary amyloidosis.
- Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of Disease progression.
- Improvement in renal function and its impact on survival in patients with newly diagnosed multiple Myeloma.
- Occurrence and prognostic significance of cytogenetic evolution in patients with multiple Myeloma.
Schools
Boston University School Of Medicine
Mayo Grad School Med
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Central Nervous System Lymphoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Mayo School of Graduate Medical Education -
Boston University School of Medicine
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1174503684 | |
| NPPES Provider LastName | LUST | |
| NPPES Provider FirstName | JOHN | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 256.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1174503684 |
| Last Name Of The Provider | LUST |
| First Name Of The Provider | JOHN |
| View All |
Similar Doctors
|
|
Dr. Aref Al-Kali, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Virgil F. Fairbanks, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Scott H. Kaufmann, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Diane M. Pierson, DO |
|
|
Dr. Martha Q. Lacy, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Michelle A. Elliott, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wei Ding, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jessica L. Geiger, MD |
|
|
Dr. Richard J. Bram, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ryan A. Wilcox, MD |
|
|
Dr. Rahma M. Warsame, MD
This Doctor is OpenDoctor Recommended.
|